organ transplant rejections

Eli Lilly Lilly
Biotech

Lilly pays CSL $100M for IL-6 drug that flunked transplant study

Lilly is paying $100 million for the right to develop a phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.
James Waldron Feb 18, 2026 5:07am
A doctor with a graphic representation of the lungs

Thermo Fisher launches biopsy test to assess lung rejection risk

Oct 9, 2025 10:50am
kidney transplant organ

Cell therapy allows kidney recipients to cut immunosuppressants

Nov 2, 2023 10:00am
Organ transplant

Immunosuppressant antibody curbs chronic transplant rejection

Apr 24, 2023 11:05am
layoffs job cuts workforce reduction layoff

Talaris lays off 95% of workforce after fruitless deal hunt

Apr 17, 2023 9:38am
organ transplant surgery cooler organ transplantation

Talaris ends recently restarted kidney transplant studies

Feb 16, 2023 11:00am